Nearly all people with systemic lupus erythematosus (SLE) treated with iCell Gene Therapeutics’ dual-target CAR T-cell therapy achieved…
Articles by Steve Bryson PhD
Discontinuing glucocorticoid therapy after achieving remission did not increase the risk of symptom flare-ups in people with systemic lupus…
Different combinations and elevated levels of antiviral immune signaling proteins, called interferons (IFNs), were associated with differences in the symptoms…
A 27-year-old woman with hard-to-treat systemic lupus erythematosus (SLE), the most common type of lupus, became the first patient…
The U.S. Food and Drug Administration (FDA) has cleared a clinical trial to evaluate the safety and preliminary effectiveness of…
The U.S. Food and Drug Administration (FDA) has granted permission for Atara Biotherapeutics to test its lupus nephritis treatment candidate…
Modified anti-inflammatory T-regulatory immune cells, known as Tregs, were able to suppress autoimmune activity in cells and in a mouse…
Brepocitinib, an investigational oral therapy, failed to show any benefits beyond a placebo in a Phase 2 clinical trial that…
Adding Gazyva (obinutuzumab) to standard-of-care therapy for two years reduced the risk of treatment failure, diminished kidney function…
The U.S. Food and Drug Administration (FDA) has approved Nkarta’s request to launch a clinical trial in the U.S. to…